SEC filing · 8-K

Lantern Pharma Inc.: Material agreement

Lantern Pharma raised approximately $4.0 million in gross proceeds through a registered direct offering and concurrent private placement of warrants.

Filed September 30, 2026

Mixed for the company

What happened

Lantern Pharma entered into a securities purchase agreement with an institutional investor on September 28, 2026.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to Lantern Pharma Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.